drugset / Trial / NCT03067597

An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term

NCT03067597

Phase 3 Completed 68 enrolled Ferring Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

To demonstrate the efficacy of controlled-release dinoprostone vaginal insert (DVI) for cervical ripening success (either Bishop Score (BS) ≥7 or vaginal delivery) within 12 hours of vaginal insert administration.

Timeline

Start
2017-02-22
Primary completion
2018-02-24
Completion
2018-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Dinoprostone Other / unclassified 10 mg Other

Indications